Tesamorelin: A Research Overview

Introduction

Tesamorelin (development designation TH9507; brand name Egrifta) is a synthetic 44-amino acid peptide analog of endogenous human growth hormone-releasing hormone (GHRH). Developed by Theratechnologies Inc., a Canadian biopharmaceutical company headquartered in Montreal, it received its first United States Food and Drug Administration (FDA) approval in November 2010 — the first and, at the time of this writing, only GHRH analog to achieve FDA approval for a human therapeutic indication. Its pharmacological interest centers on its engagement of the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, initiating GH-axis signaling through a pathway thoroughly documented in peer-reviewed primary literature.

Background

The GH axis — comprising hypothalamic GHRH, anterior pituitary somatotrophs, circulating GH, and the downstream mediator insulin-like growth factor-1 (IGF-1) — has been the subject of sustained endocrinological research since the isolation of GHRH in the early 1980s. Synthetic analogs of GHRH have been investigated as research tools for characterizing pituitary GH secretion dynamics and as potential therapeutic agents where GH-axis dysregulation has been documented.

Tesamorelin's clinical development program was focused on HIV-associated lipodystrophy, a recognized metabolic complication associated with long-term combination antiretroviral therapy (HAART), characterized by an aberrant redistribution of adipose tissue including accumulation of visceral adiposity. Falutz and colleagues reported the first large phase 3 evidence base for tesamorelin in this context in publications beginning in 2007, culminating in the pivotal trials that supported FDA approval [1,2].

Chemistry and Structure

Tesamorelin comprises the complete 44-amino acid sequence of endogenous human GHRH(1-44)-NH₂ with a single N-terminal modification: the conjugation of a trans-3-hexenoic acid moiety to the alpha-amine of the first amino acid residue (tyrosine). This modification was engineered to confer resistance to enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV), which rapidly inactivates native GHRH in the circulation by cleaving the first two amino acids, rendering the endogenous peptide biologically inactive within minutes of secretion [3].

The trans-3-hexenoic acid conjugate does not alter the peptide's primary receptor-binding domain. The biologically active sequence responsible for GHRH receptor engagement is contained in the first 29 amino acids of GHRH; the full 44-residue sequence and C-terminal amidation are retained in tesamorelin, reflecting the complete endogenous architecture of human GHRH [3].

The molecular weight of tesamorelin is approximately 5,135 daltons. It is formulated as a lyophilized powder reconstituted in sterile diluent for administration in clinical settings.

Pharmacological Classification

Tesamorelin is classified as a GHRH receptor agonist. It belongs to the broader pharmacological family of growth hormone secretagogues, which encompasses both GHRH analogs (which act at the GHRH receptor on pituitary somatotrophs) and growth hormone-releasing peptides (GHRPs), which act via the ghrelin/GHS-R1a receptor. Tesamorelin's mechanism is specific to the GHRH receptor pathway; it does not engage the GHS-R1a receptor that mediates the actions of GHRPs such as ipamorelin or hexarelin.

The GHRH receptor (GHRH-R) is a class B G protein-coupled receptor expressed predominantly on anterior pituitary somatotroph cells. Activation of GHRH-R by tesamorelin initiates a Gs-mediated intracellular cascade involving cyclic AMP (cAMP) accumulation and protein kinase A activation, leading to GH synthesis and pulsatile secretion [4]. Because tesamorelin acts upstream of pituitary GH release rather than replacing GH directly, the normal somatostatin-mediated negative feedback loop remains intact, and IGF-1-mediated feedback on the hypothalamic-pituitary axis is preserved.

This mechanistic distinction — preserving endogenous GH pulsatility and the negative feedback architecture of the GH axis — differentiates GHRH analogs from exogenous recombinant human GH (rhGH) administration, where continuous supraphysiologic GH exposure bypasses normal regulatory mechanisms. It is this pharmacological specificity that has made tesamorelin a significant research tool for investigating GH-axis physiology. The signaling cascade underlying this specificity is examined in detail in the tesamorelin mechanism of action article.

Regulatory Status

The FDA granted initial approval to tesamorelin (Egrifta; NDA 022505) on November 10, 2010, for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [5]. This made tesamorelin the first FDA-approved GHRH analog and the first pharmacological agent specifically approved for HIV-associated lipodystrophy in the United States — a milestone in both GHRH-analog pharmacology and HIV metabolic medicine.

In May 2019, a reformulated version designated Egrifta SV (Single Vial) received FDA approval via a supplemental application. The SV formulation delivers a more concentrated solution requiring a simplified one-step reconstitution process compared to the original two-vial preparation.

A further reformulation, Egrifta WR (Weekly Reconstitution, designated F8), received FDA approval of a supplemental biologics license application in March 2025. The WR formulation is designed to allow weekly reconstitution rather than the daily preparation required by earlier formulations, reflecting Theratechnologies' continued investment in formulation optimization [3].

Tesamorelin is not approved for any indication beyond the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Its regulatory status as a prescription pharmaceutical is distinct from its availability as a research-use-only material. Research-grade tesamorelin from SpartaLabs is verified for identity and purity by independent third-party analysis.

Discovery History

The scientific lineage of tesamorelin begins with the isolation and structural characterization of endogenous GHRH. In 1982, Guillemin, Rivier, and colleagues reported the characterization of a 44-amino acid growth hormone-releasing factor from the pancreatic tumor of an acromegalic patient, publishing the structure in Science [6]. A homologous 40-residue form was independently characterized by Rivier and colleagues from a second tumor specimen, published in Nature the same year.

Human hypothalamic GHRH was subsequently confirmed to share the sequence of these tumor-derived peptides, establishing the foundation for GHRH receptor pharmacology.

Theratechnologies initiated a program to develop a stabilized GHRH analog capable of sustained therapeutic engagement of the GHRH receptor. The key innovation — N-terminal conjugation of trans-3-hexenoic acid — was developed to address DPP-IV-mediated degradation, extending the molecule's effective plasma half-life relative to native GHRH. The resulting compound was designated TH9507 in preclinical and early clinical stages before receiving the international nonproprietary name tesamorelin.

Phase 3 clinical development was conducted across two pivotal randomized trials (LIPO-010 and LIPO-011) enrolling HIV-infected patients with excess visceral adiposity, which provided the evidence base for FDA approval.

References

1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. DOI: 10.1056/NEJMoa072375

2. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. PMID: 20101189

3. National Library of Medicine. Tesamorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases; 2019. Available at: https://www.ncbi.nlm.nih.gov/books/NBK548730/

4. Goldenberg N, Barkan A. Factors regulating growth hormone secretion in humans. Endocrinol Metab Clin North Am. 2007;36(1):37-55. PMID: 17336731. DOI: 10.1016/j.ecl.2006.11.003

5. U.S. Food and Drug Administration. Summary Review for Regulatory Action: Egrifta (tesamorelin for injection), NDA 022505. Silver Spring: FDA; 2010. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000SumR.pdf

6. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-7. PMID: 6812220. DOI: 10.1126/science.6812220